Eating Behavior Associated With Weight Regain after Dietary Intervention in Obese Female
Journal Title: Journal of Diabetes and Obesity - Year 2016, Vol 3, Issue 2
Abstract
The aim of this study was to test the association of eating behavior with weight loss and weight regain after dietary intervention in obese females Twenty-nine obese females were included in this study Eating behavior using the Three-Factor Eating Questionnaire TFEQ which measures uncontrolled eating emotional eating and cognitive restraint eating was tested for its association with weight loss baseline to 3 months and weight regain 3 to 15 months Uncontrolled and emotional eating at the baseline was associated with weight regain although cognitive restraint eating was associated with weight loss Information on eating behavior may help to identify people who require additional support to maintain a reduced body weight after dietary intervention in obese females
Authors and Affiliations
Naoki Sakane
Keywords
Related Articles
- EP ID EP417847
- DOI 10.15436/2376-0494.16.995
- Views 80
- Downloads 0
Effect of Obesity on the Time Required Achieving a FEO2 of 90% during Preoxygenation
An end-expiratory oxygen (FEO2) concentration > 90% is desirable prior to tracheal intubation. We hypothesized that the time required for pre oxygenation to achieve an FEO2 of 90% was related to patient Body Mass Index (...
Fructose Intake and Circulating Triglycerides: An Examination of the Role of APOC 3
Fructose consumption can lead to marked increases in plasma triglycerides in both humans and laboratory animals. We have observed that overnight access to a 16% fructose solution can promote hypertriglyceridemia in rats....
Herbal Anti-Hyperglycemic Compound Improves Glycemic Control and Insulin Sensitivity in Diabetic Rats
Objective: To study the effect of HPLC purified herbal anti-hyperglycemic active compound (FIIc) isolated from the fruit pulp of Eugenia jambolana in diabetic rats. Methods: 24 male wistar rats were taken and diabetes wa...
Addition of Metformin to Liraglutide, A GLP-1 Receptor Agonist, Improves Glycemic Control in Patients with Type 2 Diabetes Mellitus
Background: The maximum permissible dose of liraglutide, a GLP-1 receptor agonist, under the Japanese Heath Insurance system is 0.9 mg/day. We determined the effects of adding metformin to liraglutide therapy in Japanese...
The Different Association between Metformin and Sulfonylurea Derivatives and the Risk of Cancer May be Confounded by Body Mass Index
Aim: Several studies in large databases suggest that in comparison to glucose-lowering sulfonylurea derivatives, metformin is associated with a reduced risk of cancer in patients with diabetes. As many databases miss rel...